News
Obinutuzumab provides strong early responses in untreated MCL
AMSTERDAM – A minimal residual disease rate as high as 85% is “unprecedented” in this population of patients, the lead investigator of the LYMA-...
News
AAD’s augmented intelligence position statement provides look to the future
A blueprint for the future of
News
Venetoclax plus ibrutinib appears to suit elderly and high-risk patients with CLL
The combination of venetoclax and ibrutinib outperformed previous reports of either of the two agents alone.
News
Daratumumab regimen shows benefit in transplant-ineligible myeloma
The alkylator-free regimen of daratumumab plus lenalidomide and dexamethasone appears safe and effective for patients who are ineligible for stem...
News
Local consolidative therapy shows benefit in oligometastatic NSCLC
Patients treated with local consolidative therapy had a median overall survival of 41.2 months, compared with 17.0 months among patients treated...
News
Eosinophil levels affect glucocorticoid response in mild, persistent asthma
Two recent studies presented at the American Thoracic Society’s international conference demonstrated the benefits of glucocorticoid therapy among...
News
PET imaging at diagnosis improves oropharyngeal cancer outcomes
In patients with oropharyngeal cancer, initial staging with PET imaging was associated with better cancer-specific survival than staging with...
News
Atypical case of cutaneous MCL mimics SPTCL
The unusual case shows the importance of molecular cytogenetics and/or immunohistochemistry when making a diagnosis in panniculitis-type lymphomas...
News
ctDNA predicts recurrence in nonmetastatic colorectal cancer
The sensitivity of ctDNA testing for disease recurrence was 100%, compared with 60% for CEA testing, in an observational study of 58 patients with...
News
ARCHES: Enzalutamide improves mHSPC survival regardless of baseline PSA
For men with metastatic hormone-sensitive prostate cancer, enzalutamide with ADT offers longer radiographic progression-free survival compared...
News
Systemic therapies are impacting melanoma’s prognostic factors
Systemic treatments have altered the disease kinetics for patients with melanoma.
News
CAR T-cell therapy bb2121 performs well in phase 1 trial of refractory multiple myeloma
The objective response rate of 85% among 33 heavily pretreated patients suggests “promising efficacy.”
News
Idelalisib shows long-term safety, efficacy for relapsed CLL
The long-term data confirm that the addition of idelalisib to rituximab significantly improves outcomes for patients with relapsed CLL. However,...
News
Circulating tumor cells predict NSCLC survival, but clinical role uncertain
GENEVA - CTC counts of at least 5 cells per 7.5 mL were associated with reduced overall survival in a retrospective analysis involving 550...
News
BWH classification system better predicts outcomes in HNCSCC
The Brigham and Women’s Hospital tumor classification system was better than the AJCC 8 in predicting metastases and death among 459 patients with...